Because lymph oma fr equently manifests as a neck mass, otolaryngologists are of ten the first to evaluate and diagnose it. Exc isional biopsy oflymph nodes generally provides the definitive diagnosis. Aft er diagnosis, however, the otolaryn gologist 's involvement generally wanes as subsequent treatm ent of the pat ient is provided by an oncology team. Neverth eless, it is important f or the otolaryngolo gist to be familiar with current concepts in the comprehens ive evaluation and treatm ent of lymphoma patients. This knowledge allows us to participate in and facilitate timely testing, which helps avoid undue delays betw een the docum entation of physical fi nding s and the initiation oftreatm ent. Otolaryngologists also need to be up to date on recent developm ents in the treatment of lymphomas in order to be able to answ er questions regardin g staging and prognosi s, to make the prop er referrals, and to help our pat ients understand current controv ersies and treatment practices.
Introduction
Lymphoma is a lymph oproliferative disorder that is ofte n identified first by oto laryngo logis ts and head and neck surgeons . Once the diagnosis is made , however, the patient is treated principally with radiation therapy and by medical oncologists. Thu s, as the patient' s treatment progresses, the involvement of the otolaryngologist tend s to dimini sh.
There are many controversies in the management of lymphoma, from categorization to stag ing to treatment options. Familiarity with these controversies and with the current state of the art in diagnosis and treatment is esse ntial in order for the otolaryngologist to partici pate in a meaningful way as a member of the multidiscip linary team. Although the lymphoma management team includes onco logis ts, general surgeons, radio logi sts, radiation onco logists, and others, otolaryngologi sts are often the ones who make the diagnosis following an eva luation ofa neck mass, and we establish a rapport and relation ship with the patient. Patients and referring phy sicians look to otolaryngologists for expertise in the management of neck masses. It is important for us to remain knowledgeable resources for both our patients and primary care physicians and to remai n involved in and fami liar with total patient manage men t beyond the biopsy.
Disease characteristics
Lymphoma accounts for about 4% of all new cases of cancer in the United States every year. ' It is second only to squamous cell carcinoma as the most common head and neck cancer.I Lymphoma is typically cate gori zed as either Hodgkin' s or non-Hodgkin's disea se.
Disease prese ntatio ns vary accordi ng to their natural histories. Hodgki n's disease typically sprea ds by contiguity, while non-Hodgki n's usually does not. About 80% of Hodgki n's patients have cervical ade nopathy, wherea s abo ut 33% of non-Hodgkin's patients have noda l disease in the neck .I Patients with both type s of disease can also have hematologic disorder s, media stinal complaints, central nervou s system symptoms, gastrointestina l disorders, or other difficulties.
Hodgkin 's disease. Hodgkin' s disea se usually affects patients in the third and the seventh decades of life, and it is more common among men than women. The already higher relative risk of Hodgki n's disease confer red by a positive family history rises tenfold when a same-sex sibling has the disea se.I A possible cau sal relation ship exist s between Hodgkin' s disease and the prese nce of Epstein-Barr virus (EBV). ' The cell of orig in in Hodgkin ' s disease is not yet well defined. Hodgkin's disease is char acterized by the presence of the pathog nomon ic multinucleated Reed-Sternberg cell. The cellular background defines the four histologic subtypes : nodular sclerosis, lymphocyte predominance, mixed cellu larity, and lymph ocyte depletion.' The cellu- CONTRAI NOI CATIONS r evcnoxacn is contraindicated in persons with a history 01hypersensitIVI ty to levcnoxacn. quinolone antimicrobialagen ts. or any other componentsollh is product. t y OFLEVOELO XACININ PEDIATRIC PATIENTS ADOLESCE NTSIUNDERTHEAGE OF18 YEARS) PBEG · . (See PRECAUTIONS: Pediatric Use. Pregnancy, and NursingMolhers subseclions.) In immature ratsanddogs. the oral andintravenous administration ctlevotloxacin increased the incidenceand severity 01osteochondrosis. Ot her uuorccoooro nes also produce simi lar erosionsin the weight bearing joints and other signsof arthropathy in imma tureanimalsof various species. (See ANIMAL PHARMACOLOGY infutlPrescribinglntcrmation.) Convulsions and toxic psychoses have been reported in patientsreceivingqurnoicnes . including levotloxacin. Ouinclones may also cause increased intracranial pressureandcentralnervoussystemstimulation which may lead to tremors. restlessness. anxiety. lightbeadedness. confusion. hallucinations. paranoia. depression, nightmares. insomnia. and, rarely, suicidal thoughts or acts. These reactionsmay occur foll owingthefirstdose. If thesereactions occurin patients receiving levoncxacin. thedrugshouldbediscontinuedand app ropri atemeasures instituted.As withother quinclones. levonoxacin shouldbeusedwithcaution in patients wi th aknown or suspectedeNSdisorder thatmaypredispose toseizuresorlowerthesei zurethreshold(e.g.•severecerebral arte riosclerosi s. epilepsy) or in thepresenceof other riskfactorsthat may predisposeto seizures or lower theseizurethreshold (e.g..certaindrugtherapy . renal dysfunction.) ISee PRECAUTIONS: General. Inform ationforPatients. DrugInteracfions andADVERS EREACTIONS.) Serious and occasionally fatal hypersensitivityand/or anaphylactiC reactions have beenreport edin patients receivi ng therapywith qumoicnes. includinglevolloxacin. Thesereac tions ottenoccur followingthe first dose. Some rea ctionshavebeen accompaniedby car diova scular collapse. hypotension/ shock. seizure. loss ofconsciousness, tingling.angioedema(incl uding tongue. laryngeal.throat. or facial edema/swelling). airway obstruction (inclUdingbroncnospasm.short ness of brea th. and acuterespiratorydistress). dyspnea. urticaria. itchi ng. and otherseriousskin reactions. Levclloxacin should bediscontinuedimmedi ately at thefirstapp earance of a skin rashor any othersignofhypersensitivi ty. Seriousacutehype rsen sitivity reactions mayrequ iretreatmentwith epinephrineand other resu scitativemeasures. including oxygen. intravenous fluidS. antihistamines. corticosteroids. pressor amines. and airwayrnanaqement. asclinically indicated .I SeePRECAU TIO NSandADVERSE RE ACTIONS.) Ser iousandsometimestatal events . some dueto hypersen sitivity. andsome dueto uncertain etiology. havebeen reported rarely in patients receiving therapy with quinotones. incl uding levouoxacln. These events may be severe andgenerally occur101l 0wing the administrat ion of multiple doses. Clinical manifestations may includeoneor more of the following: fever. rashor severe derrn atologic reactions (e.g.•toxicepidermal necrotysts. Stevens-Johnson Syndrome): vasculitis;arthralgi a; myal gia; serumsickness; allergic pneumonitis; interstitial nephritis: acute renal insufficiency or fail ure; hepatitis; jaundice; acute hepat ic necrosis or fai lure : anemia. includinghemolytic andaplastic: thrombocyto penia. incl udingthrombotic thrombocytopenic purpura; leukope nia: agranul ocyt osis; pancytopenia;and/orotherhematolog icabnormalities. Thedrugshouldbediscontinuedimmediatelyat thefirst appearance of askin rash or anyother sign of hypersensitivity and supportive measures insti tuted. (See PRECAUTIONS: Informat ionfor Pati ent s and ADVERSEREACTIONS.) Pseudom embranous colitis has been reported with nearly all antibact erial agents, Including levolloxacin, and may range in severity from mild to lite·threafening . Therefore, it Is Importantto consider this diagnosis in patients whopresentwith diarrhea subsequenl to the adminisfralion ol any anlibacterial agenl. Treatment with antibacterialagents alters thenormalfloraof thecolonandmay permit over grow th 01clostridia. Stud iesindicatethat a toxinproduced by Clos tridiumdirtic;leis oneprimarycauseol-anti biotic-associat edcolitis." After the diagnosis 01pseudome mbranouscolitis has beenestablished. therapeutic mea sures should be initiated. MIld cases of pseudomembranouscolitisusual ly respond to drugdiscontinuationalone . Inmoder ateto severecases. considerationshould begiven tomanagement withfluidsandelectrolytes. proteinsupplementation.andtreat mentwithanantibacterialdrugclinica llyetrecnv eagainst C. dirt/dIecolitis. (Se eADV ERSEREACTIONS.) Rupturesof theshoulder. hand, orAch illestend onsthatrequiredsurgical repair or resultedin prolongeddisab ility havebeenreported in patients receivingquinclc nes. including levctloxacn. Levcflcxacin shouldbediscontinued if thepatient experiences pain. inflammation. or rupture 01a tendon. Pat ients should rest and rel rai n fromexerciseuntilthediagnosis of tendinitis or tendon rupturehas been conf ident lyexcl uded. Tendon rupturecan occurduring or altertherapywithquinolones. inclUding levolloxacin. As with otherqcectone s. disturbancesof blood glucos e. including symptomat ic hyper -andhypog lycemia. have been reported. usually in diabetic patients receivingconcomitant treatment withanoralhypoglycemicagent (e.g.•glyburidelglibenclami de)or with insulin. In thesepatent s, careful monitoring of blood glucoseis recommended. II ahypoglycemic reaction occurs in apatient being treated with levencxacin. levcfloxacinshould bediscont inuedimmediately and appropriate therapy should beinitiated immediately. (See DrugInteractions andADVERSE REACTIONS.) Some quinoloneshave bee n associated with prolongation of the aT interval on the elect rocardiogramand infreq uentcases of arrhythmia. During pcst-marketinq surveillance . ext remely rarecases of tcrsades depotntes. havebee n reportedin patients taking levofloxacin. These reports generally involve patients who had other concurrent medical conditions and the relationship to levotloxacinhas not been establ ished. Among drugs known to causeprolongation 01theaT interval . the riskof arrhythmiasmay beredu ced byavoiding useIn thepresenceof hypokalemia, significant bradycar dia. or concurrent treatmentwith classlaor class llla nt'arrbythmicaqents. to discontinuetreatment andinform their phys icianil theyexperience pain.inflamma tion, or ruptureof a tendon, andto rest and retrain fromexercise until thediagnosis of tendinitis or tendonrupturehasbeenconfidently excluded: thatlevofloxacin maybeassociated wi th hypersensitivity reactions. even followingthefirst dose, andto discontinue the drug at thefirst.sign of.a ski n rash. hives or othe r skin reactions. a rapi d heartbeat. difficultyin swallowing or breathing. anyswelling suggestmg angioedema le.g.• swelling of the lips, tongue. face. fightness01the throat.hoarseness), or other symptoms 01an allergicreaction. ISeeWARNING Sand ADVERSERE ACTIONS): to avoi d e~cessive sunlight orartificial ultraviolet lightwhile receivinglevofloxacinand10discontinuetherapyif phototoxic ity (i.e.• ski n eruption)occurs; that if they arediabetic and arebeingtreated with insulinoran oralhypoglycemic agent andahypoglycemic reaction occurs, they should discontinuelevoftoxaci n andconsult aphysician. (See PRECAUTIONS: General andDrugInteractions.); that concurrentadmi nist rationof war 1a rinandlevofloxacinhasbeenassociatedwi th increasesof theInternational NormalizedRa tio (INR) or prothrombin timeand clini cal episodes 01bleed ing. Patients shou ld notily their physician jf theyare taking warfarin. thatconvulsions havebeen reported in patients taking Quinolones, including levofl oxacin. and to notily their physician before taking this drugif there is ahistoryof this condition. Drug Interactions Antacids, Suc ralfate, Metal Cali ons, Multivilamins LEV AQUINTablets: Whi le thechelation by divalent cationsis less markedthanwith otherQuinolones. concurrent adm inistration of LEV AQUINTablets with antacidscontainingmagnesium, or alum inum. aswellassucralfate . metal cationssuch asiron. andmultivitaminpreparat ionswithzincm~y interferewitht~e . gastrointestinalab sor~tion of levefloxacin. resultingin systemic level s considerably lowerthandesired. Tablets W Ith antacidscontaining magnesium. alummum. aswellassucral fate, metal cations suchasiron. and multivitamins preparationswith Zi ncorVid .eX®.( Oid~Osine ) . ch ewablelbuffer~d tabletsor theped iatricpowder fororalsolu tion. may substantial ly interfere withthegastrointes tinalabsorptionoflevoll oxacin. resuiling in systemi c levels considerably lowerthandeSired.
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Theseagents shouldbetakenatleast 1\'10hours before or1\' /0 hoursatterlevofl oxacinadministrat ion.
LEVAOUINInjection: There arenodata concerninganintera ctionof Intravenous quinolones with oral antacids. sucralfate . multivitamins.VideX®. (Didanosine) , or metal cations. However . noquinolone shouldbeco-a dministere d withanysol uti on containingmulti · valentcat ions,e.g.•mag nesium.through thesame intravenousline. (See DOSAGE AND ADMI NISTRAnDN infullPre scrib ingInforma tion.) Theophylline: Nosignilica nt effe ct of levofloxacin on theplasmaconcentrations. AUC. andother disposition parameters for theophyllinewasdefectedinaclinica l studyinvolvi ng14healthy volunteers. Simi larly.no apparent effect of theophyllineonlevolloxacin absorption and disposition wasobserved. However. concomitant administration of othe r quinolones with theophylline has resulted in prol ongedel iminationhalf·tile, elevatedserum theophyllinelevels, and a subsequent increasein theriskof theophylline·rel ated adverse reactions in the patient popul ation. Therefore, theophylline levels should beclose ly monitoredandappr opriate dosage adjustmentsmade when levoucxacin is co-acmmist ered, Adverse reactions. including seizures. may occur with or wi thout an elevation in serum theophyllinelevels. (SeeWARNINGS and PRECAUTION S; nenerar. ) Warfarin: Nosignificant ettectof.ll Ioxaci n on th~peak plasmaconcentrations. AUC . and othe r disposition par ameters lor R-and S-warfari n wasdetectedin a c1lmcal studyinvol vmg healthy volunteer s. Si milarly. no apparent effect of warf ann on levctlcxacin absorption and dispositionwas observed. Therehavebeen reports duringthepost-mark etingexper iencein patients thattevcnoxacm enhan ces the enecrs01warfarin. Elevat ionsof theprothrombin timein the sening 01concurrent warfari n and levoucxacm usehave beenassociatedwithepisodes of bleeding. Prothrombinlime.InternationalNormaliz edRa tio IINR). or other suitableanticoagul ation testsshould be closely monitoredif levonc xacn is administered concomit antly with wartann. Patients should alsobemonitored for evi denceof bleeding. C ycl o sp o~i n e : Nosignif icant elfect. of levolloxacin.on the peak plasma concentrations. AUC. and other disposition parameters lor cyclosponne wasdetected in a cllmcal studyinvolving healthy volunteers. However . el evated serumlevels01cyclosponnehave been reported in thepatient population when co-administeredwithsome other quinolones. LevottoxacinCmax andktwere slightly lower while Tm ao andtltZwere slightlylonger in the presence 01cyclosporinethanthose observed in otherstudies without concomitant medication. The differences, however, arenotconsidered to be clinically significant. The refore, nodosage adj ustment is required for levouoxactn or cvcrospome when administeredconcomitantly. Digoxin: No significant effect of levo lloxacin onthe peak plasma concentrations. AUC, andother disposition parameters lor digoxin wasdetectedin aclinical studyinvolvinghealthy volunteers. Levcnoxacmabsorption anddispositionkinetics were similar inthepresence or absence of digoxin. Therefore. nodosage adjust ment for levcftoxaon ordigoxinis required when administeredconcomitant ly.
Probenecid and Cimelidine: Nosignificant ert ect of probenecid or cimetidineonthe rate and extent otlevotloxacin absorption was observedin a clinicalstudyinvolvinghealthy vol unteers. TheAUCandt1/2onevonoxaonwere27-38% and30%higher.respectively . whileClIFandCLRwer e21·35%lower duringconcomitant treatment withprobenecid or cime tidinecomp aredto levofloxacin alone. Al thoughthese differences were statistically signif icant.the changes were not high enoughto warrant dosage adjustment lor levolloxacin whenprobenecid or cimet idineis co-admini stered . Nen-steteidal ant i-inflammafory drugs: The concomitant administrat ionof anon-steroidalanti-inflammatorydrugwith a quinclcne. inclUding levotlcxacin. mayincrease the risk of CN S stimulation and convulsive sei zures. (See WARNINGS and PR ECAUTI ONS: GeneraL) Antidiabetic agents:Disturbancesofbloodglucose. includinghyperglycemiaandhypoglyce mia, havebeenreportedinpat ientstreated concomitantlywithquin clones and anantidiabetic agent. Therelore. careful monitoringof bloodglucoseis recommendedwhen these age ntsareco-administered. Carcinoge nesis Mytagenesis Imoajrmenl 01f ediljty Inalifet imebioassayinrats.levoncxacn exh ibitedno carcinogenicpotentiallol1owingdailydietaryadm inistrat ionfor2yea rs: thehigh· estdose (100mglkglday) was 1. 4 times thehighest recommended human dose(750mg) based upon rel ative body surfacearea.
Levotlcxacinwasnotmutagenic in thefoll owingassays: Ames bacterial mutation assay (5. typhimuriumand 
forwardmutat ionassay.mousemicronucleus test.mouse dominant lethaltest. ratunscheduledDNAsynthesis assay. andthemouse siste r chromatid exchange assay. II was positivein thein vitrochromosomal abe rrat ion (CHL cellline)and sister chromatidexchange (CHUIUceltline) assays. Levofloxacin caused no impair ment 01 fert ility or reproductive performance in rats at oral doses as high as 360 mglkglday, corresponding to 4.2times thehighest recommended human dose based uponrelativebody surface area and intravenous doses ashigh as100 mg/kglday, corresponding to 1.2times thehighest recommendedhuman dose based uponrelativebody surface area. pregnancy' Teralogenic Effects pregnancyCategory C tevcnoxacn wasnot teratogenic in ratsatoraldosesas high as810mglkglda y whichcorresp ondsto 9.4timesthehighest recommended humandosebased upon relativebody surface area . or at intravenous dosesas highas 160mglkgldaycorrespondingto 1.9 times thehighest recommendedhuman dose baseduponrel ativebody surf acearea . Theoral dose of810mglkglday toratscaused decreased fetal body wei ghtandincreased fetalmortali ty. Noteratogenicitywasobservedwhen rabbits were dosed orallyas high as 50mglkgldaywhichcorre spondsto 1.1timesthehighest recommendedhumandosebasedupon relativebody surfacearea. or when dosed intravenously as highas25mglkglday. correspondingto0.5timesthehighe strecommended human dosebased uponrelative bodysurf acearea .
There are. however. no adeq uateandwell-c ontrolled studiesin pregnant women. tevcnca cn should beused duringpregnan cyonly if thepotential benefitjustif ies thepotentialriskto the fetus. (See WARNINGS.) Nyrsing Mgthers Levcnoxacin hasnot been measuredin human milk. Based upon data lrom olloxacin. it canbepresumed that levolloxacin will be excre tedin humanmilk. Becauseof thepotentialtor seriousadverse rea ctions fromlevofloxacin in nursinginfants. a decisionshoul d be made whet her to discontinue nursing or to discont inuethedrug. taking intoaccount theimportance 01thedrug to themother. Safety andeffectiveness in ped iatric patients andadolescents below theageof 18years have not been established. Ouinotcnes . inclUding levoflcxacin. causearthropathyandosteochondrosis in juvenile ani malsof severa l species. (See WARNING S.)
In phase 3 clinic altrials.1,190 tevonoxacln-trea ted patients (25%) were2: 65years of age . 01these, 675 patients (14%)werebetween theagesof 65and 74and 515patients (11%)were 75 yearsorolder.Nooverall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experi ence has not identified differences in responses between theel derly and younger pat ients, butgreater sensitivity of some olderindividuals cannot beruledcut. The pbarmacokinetic propert ies of levcflcxacinin youngeradults and elderly adults do notdiNer signi licant ly when creatinine clearanceistaken intocons ideration. However sincethedrugis known tobesubstantiall y excreted bythekidney. theriskof toxic reactions to thisdrugmay begreater in patients withimpaired renal function. Because el derly patientsaremorelikely to havedecreased renal function, careshould betaken in doseselect ion, andit maybeuseful to monitor renalfunction. ADVERSERE ACTIONS Theincidenceof drug-related adverse reactionsin pati entsduri ngPhase3clini cal trialsconductedinNorthAmerica was6.3%.Among pat ientsreceivinglevoucxacintherapy. 3.9%discont inued levofloxacintherap y duetoadverse experiences. Theoverall inci dence. type anddistribution of adverseevents wassimilar in patients receivi ng levotlcxacin doses 01750mg once daily compared to patients rece ivingdosesfrom250mgonce dailyto500mgtwicedaily.
Inclinicaltrials . thefollowingevents were cons ideredlikelytobedrug-relatedin pat ientsreceivinglevof loxa cin: nausea 1.3' 10. diarrhea 1.0%.vaginitis0.7' 10.insomnia 0.5%.abd ominal pain0.4%. flatulence 0.4%, pruritus 0.4' 10.dizziness 0.3%,dyspepsia0.3%. rash0.3%, genital moniliasis0.2%,taste perversion 0.2%.vomiting0.2%,const ipat ion0.1%.fungal infect ion0.1%. gen ital pnmns 0.1%. headache 0.1%.moniliasis0.1%. nervousness 0.1%.rash erythematous 0.1%. urt icar ia0.1%. In clini cal trials. the following events occurred in >3% 01 pat ients . regardlessof drug relationship: nausea7.2%. headache 6.4%. diarrhe a 5.6%. insomnia4.6%, injection sitereaction 3.5%, constipation 3.2%. In clinical trials. thefollowingevents occurredin 1 to 3% of patients, regardless 01drug relationshi p: dizzi ness 2.7%.abdominal pain2.5%.dyspepsia 2.4%. vomi ting 2.3%,vaginitis 1.8%. injection site pai n 1.7%. flatulence 1.5%. pain 1,4%. pruritus 1. 3%. sinusitis 1.3%. chest pain 1.2%, fatigue1.2%, rash 1.2%. back pain 1.1%. inject ion site inflammation 1.1%. rhinitis 1.0%. taste perversion 1.0%. In clinical trials, thefollowi ng events, of potentialmedical importance. occurred at arat e of less than 1.0% regardless of drug relationship: Autonomic NervousSys tem Disorders : postural hypotension; Bod y asa Whole - Laparotomy staging. Ever since its in ception , stagi ng by lap arot omy has prom pted much co ntroversy. This pro cedure is used to det ermine whether or not supra diaph ra gmat ic stage I an d II Hod gkin ' s disease has crossed the di aph ra gm. If it ha s, the di sease is classified as at least stage III. The essentia l q ues tio n th en becom es, Is the information gained by staging laparotomy sufficient to ju stify the means used to acquire it?
Th e rate of di scovery of path ol ogi c nod es via lap arotom y can be as high as 30% . 8 
Staging
As is the case wi th all malignancies , the stagi ng of lym ph o ma is designed to predict risk . Laparot omy and ra dio log ic studies ca n help accomplis h th is, as ca n prognostic fac tors der ived fro m re trospective ana lyses and, of course, th e clinica l exami na tio n. The A nn Arbor stag ing system is used to stra tify risk for both Hod gkin ' s and non-Hodgki n ' s lymphom a (table 2) . 6 Prop er staging ult im at el y mean s that th e patien t will ex pe rie nce ne ithe r the mo rb idity of overtreatment nor the mortalit y of un dertreatmen t. And even in ideal doses, treatments th e m sel ves ar e not ben ign. For example , radiation therap y ca n still ca use hyp oth yro idism, pneumonitis, pericarditis , steri lity, an d other problem s. Li kewi se, chemot herap y can ca use na usea and vo mi ting , neurop athies, le ukopenia , sterility, and possibly th e ind uc tio n of ac ute lar milieu might or might not have prognostic significance."
Non-Hodgkin 's disease. In th e head an d Low-grade neck, non -H od gkin ' s lymphoma is five times lymphomas mo re common than Hodgkin's disease. In fac t, it is th e second most co mmo n head and Small, lymph ocytic neck ma lignancy in and of itse lf . A sub type of non -Ho dgkin's disease, Burkitt's lyrn-Follicular, s mall cleave d pho ma , has been shown to be stro ng ly associated with E BV .' Th ere is also a strong Follicula r, mixed associatio n bet ween non-Hod gkin ' s lymphoma and hu man immuno deficiency vir us in pati en ts who have adu lt T-cell leu kemia.
In approximately 90 % of cases, no n-H od gkiri ' s disease is derived fro m B cells, while the remainder are Tvcellder ived . Most patients do no t have sys temic sympto ms ("A" sta tus) ; approxima te ly 10% of pa tients do (" B" status). T hese symptoms in clude un e xpl a ined feve r (>38°C), un e xpl ained weight loss (> I0% ofbod y we ight), and night sweats. A pat ie nt's A or B status is routinely taken into account during stagi ng , altho ug h th is re mains a subject of o ngoing de bate .
The im m unologic sta tus of the ce lls and the histol ogy of th e nod es are used to c haracterize non -H od gk in ' s lymphoma. O ve r ti me , this categorization has taken o n man y fo rm s, inc luding the si multaneous use of six differ ent systems inte rnationa lly." A mo ng th ese sys tems are th e Rappapo rt , Kiel , a nd Lu kes-Collins class ifica tions . Th e c urre nt classificatio n syste m fo r non-Hod gkin ' s lympho ma was ado pted in 1982 to pro vid e a un ify ing schema (ta ble I). In 1994 , an int e rn ati on al gro up of path ol ogi sts met and de vel op ed the re vised European-American lympho ma (REAL) classificat ion sys te m for lym ph oid neoplasrns.' The REAL sys tem was an attempt to es ta blis h a Stage more cli nicall y useful ca tegorizatio n of lymphoi d neopl asm s. E ven so, the 1982 classifica tion system is still wi de ly used .
DAILEY, SA TALO FF long term .10-13 Thi s risk has been rep orted to be abo ut 2 to 4%.10. 1 4-20Th e use of pneum ococcal vaccine ca n dec rease the risk oflate infectio n, which makes lap arotomy a more reasonable option .
In many retrospecti ve studies, researchers have tried to identi fy factors that pred ict the positi vity or negativity of stag ing laparot om y, and they have been successful in identifying certai n subgro ups of patie nts in whom the use or avoidance oflaparo to my makes sense. Leibenh aut et al studied 9 1S patient s with clini cal stage (CS) I and II Hodgkin ' s disease who underwent lap arotom y, and they were able to identi fy specific subgro ups in who m laparotomy had a low yield." Th ese patient s included wome n with CS I dise ase, patient s with medi astinum-only CS I disease, and men with CS I disease who had either lymph ocyte predominance or interfolli cul ar histologies.
All these group s had less than a S% risk of subdiap hragmatic disease. Moreover, the ir B status did not correlate with advanced disease. On the other hand , male sex in genera l and histologic findin gs of mixed ce llular ity did carry an increased risk of subdiaphrag matic disease.
Lik ewise, Mauch et al reported on 692 patients with supradia phragmatic disease who under went laparotomy.1 5 Again , wom en with CS I disease and men with CS I disease and a lymphocyte predominance had a low probability of subdiaphrag matic disease. Moreover, men who had CS I disease high in the nec k we re also in the lowprob abil ity gro up. Con versely , a high prob ability of subdiaphragmatic disea se was assoc iated with B status, male sex, age grea ter than 40 years, and mixed cellularity or lymph ocyte depl eti on on histology. Alth ough laparotom y is still the gold-s tandard stag ing pro cedure, it is ce rtainly not the only option.
Radiologic staging. Radiol ogic studies also provide useful informati on . Lymph angiograph y was once the mainstay of radiolog ic diagnosis for lymp homa, and it is still used in so me ce nters . However, co mputed tomography (CT) , mag netic reso nance imaging (MRI), gallium sca ns, and 2-[F-1 8]-fluoro-2-deoxy-D-glu co se posi tro nemission tomography (FDG-PET) have all come into use, and they provide physiologic as well as anatomic data.
CT is typi cally the primary radiologic study for lymphom a. It pro vides a rapid , cos t-effective study for both stag ing and foll owup . But it is not the best cho ice for all patient s. For example, one of the difficulties in follow ing patient s after treatm ent is that tum ors ca n still be physically present but physiol ogicall y sterilize d. Gall ium sca ns and FDG -PET are especially helpful in assess ing these cases.
Gallium scans. Dr aisma et al comp ared the utility of ga llium and MRI sca ns for detectin g med iastin al lymphoma in 189 patient s." Th ey found that the sensitivity and specificity of gallium were 90 and 97 %, res pec tively, compared with 89 and 89% with MRI. 166 Simil arly, Setoain et al studied S3 pat ient s who were imaged with both ga llium and CT after trea tment." Th ey found that the sens itivity and specificity for detectin g tum or rec urre nce we re 88 and 100% with ga llium, compa red with S9 and 72 % with CT-again dem on strating the supe riori ty of ga llium as a follow up study. Additionally, they report ed that all four of the treatm ent fa ilures in their study were ev iden t o n ga llium sca ns.
Th e value of ga llium sca ns in helpi ng guide postche mo therapy deci sion s was further docum ent ed by Stroszczynski et al in their study of 28 patient s who were im aged with both ga llium and CT Y Sensitivity and specifici ty were 94 and 100% with ga llium, co mpare d with 83 and 93 % with CT.
In a finding that is perhaps most important , Kapl an et al found that ga llium sca ns can predict co mplete and lastin g remiss ions when patient s are gallium-pos itive before treatment and gallium-negative afterward."
PET scans. Th e use of PET also merit s atte ntion.
Newm an et al studie d 16 patients who had und ergone both CT and FDG -PET prior to bein g treated ." All tumor sites that were see n on CT were also see n on PET , and three patients who had negative lapa rotomies also had nega tive abdo mina l CT and PET sca ns. PET thus demonstrate d excellen t se nsitivity and spec ific ity in this small sa mple.
Moog et al imaged 60 patient s with both mod aliti es to eva luate 740 lymph node region s." CT identi fied 160 positiv e regions, while PET ident ified all 160 plu s 2S others that were und etected by CT. PET findings result ed in the restag ing of fo ur patient s, while CT altere d stag ing in only one . Other autho rs support the use of PET , particularl y because of its va lue in detecting the activity of tum ors after treatm ent. "
In view of these findings, it appea rs to be reason able not to subject se lec ted pati ent s in low-p robabili ty ca tegories to the morbidity of lap arotomy-provid ed that they are follow ed closely wit h clinical, laboratory, and radiolog ic assessments.
Treatment
Onc e risk has been determ ined , treatm en t must be instituted that will attack the disease while sparing the patient. In both Hodgk in's and non-H odgkin' s disease, the more dissem inated the disease, the higher the risks. Suitable therapeuti c stra teg ies have been wide ly agreed upon for both diseases (table 3) . Treatment optio ns incl ude observatio n, involved-field radiation , subtotal lymphoid irradiatio n, chemo the rapy wi th or without radiation, and bone marrow transpl ant. Th e more adva nce d the disease, of course, the more agg ressi ve-and hence tox ic-the treatment. Altho ug h there are gener al treatm ent guidelines, some basic que stion s linger, and co ntrove rsy atte nds the treatm ent of all stages of disease. failed radiation therapy yields surv ival rates that are equal to those of chemotherapy alone in early-stage disease, and therefore limited radia tion as a primary treatment does not put the patient at risk for increased mortality." They also reported that relapse rates are the same after chemotherap y in both groups.
Prognosis
Pre-and post-treatment fac tors have been analyzed to help determine prog nosis in non-Hodgkin's disease. One multivariate analysis of 2,03 1 patients ident ified seve ral independe nt risk factors for poor survival." These factor s were age grea ter than 60 year s, late-stage disease, elevated serum lactate dehy drogenase levels, impaire d perfor mance status, and extranodal involvement. Th is study also found that 5-yea r survi val rates were 73 % for patients with zero or one risk fac tors, 5 1% for those with two, 43% with three risk factors, and 26% for patients with four or five. Add itiona lly, pre trea tment clinical feat ures that predicte d a relapse from com plete remission included advanced stage, age grea ter than 60, and abnormal seru m lactate dehydrogenase levels.
Certai n treatment-re lated prognostic fac tors have also been noted. Two studies found that the fas ter a patient achieved a comp lete remission, the longer he or she survived.P-" However, Kwak et al repor ted that the administration of cyc lophosphamide early during treatmen t decreased the chance of a comp lete remission and increased the cha nce of relapse from comp lete remission." Of partic ular note was the discovery by Kap lan et aI, mentioned earlier in this article, that galliu m scans can predict prolonged co mplete remissions." In their study, 70 % of patien ts who were transforme d from galliumpositive to gallium-negative by four to six cyc les of chemo therapy had long-term complete rem issions. Conversely, only 24% of patients who were still galliumpositive after treatment had long-term comp lete remissio ns.
Cellular and molecular features can also help stratify risk . One such method is to monitor the rate of tumor cell pro liferation for the presence or abse nce of Ki-67-the "nuclear proliferation antige n." Groga n et al reported that patients whose tumors had Ki-67 antigen in mo re than 60% of cells had a median survival of only 8 months, whereas those who had Ki-67 in less than 60% of cells had a median survival of 39 months."
The immunology of a tumor' s cells plays a strong role in predicting its agg ressiveness . For example, Miller et al Moreover, there is evidence that chemotherapy without radiation as a primary treatment of early -stage disease produces morbid ity and mortality rates that are somew hat comparable to those of radia tion therapy alone ." Other studies have show n that rates of cure and relapse-free sur viva l fo llow ing combination chemotherapy were comparable to those of radiation therapy alone in earlystage Hodgk in' s disease.P-" Furthermore, cons ideri ng that radiation therapy trea ts only local disease and chemotherapy treats systemic disease, staging laparotomy would become virtually useless if these data are borne out in for thcomi ng studies .
High-do se chemotherapy with evaluation for bone marrow transplant if response is inadequate
Ob servation or chemotherapy reported that when the maj or histocompatibility com plex (MHC) antige n HLA-DR was absent, median survival was only 6 month s; whe n the antigen was present , survival excee ded 2.8 years ." Moreover, 13-2 microglobulina small protein that attac hes to MHC class I molecules and which is detec tab le in serum-has been correlated directly with high tumor burdens and shortened survi val in patients with aggressive non-Hodgkiri' s lymphoma." Also , survival is correlated with the ability of a tumor to spread, and adhe sion molec ules can play a ro le in that spread. Lymphocyte homing receptors facil itate lymphocyte bind ing and extravasatio n into nodes. " Aggressive lym phom as that are negati ve for lym phocy te hom ing receptors have been reported to be less likely to dissem inate than lym phomas with greater expression.P:" Furthermore, studies have shown that abo ut half of all patient s wit h high expre ssion levels had advanced disea se, compared with slightly more than 10% who had low expression levels." :"
In conclusion , the management of lymp homa remains dynam ic. Diagnosis, staging, and treatment planning are all undergoing their own inde pendent evo lutions. We anticipate that the use of the REAL staging system will become more popular and that gallium and PET scans will rep lace stagi ng laparotomy in selec t patient groups. We also believe that less toxic chemot herapeutic regimens will play an increasing role in the treatment of early-stage Hodgkin' s disease. Otolaryngologists will cont inue to playa crucial role in diagno sing lymp homa, and so it is essential that we are knowledgeable members of the onco logic team and that we remain famili ar with the latest trends in comprehensive lymphoma care. 
